Skip to main content

RCPE's next webinar on the developement of cognitive automation solutions for the pharmaceutical industry.

APRIL 13th, 2023 // 13:00 CET

Learn more

COMPARISON OF BIOTEST HSA AND RECOMBINANT HSA FOR THE PREPARATION OF NANO ALBUMIN BOUND PACLITAXEL USING MICROFLUIDIZER® TECHNOLOGY

In cooperation with Microfluidics and Biotest, RCPE hosted a joint webinar. This session presented nab-paclitaxel technologies produced using a high shear Microfluidizer® processor.

The first FDA-approved nab drug delivery technology formulation is nanoparticle albumin-bound – paclitaxel. Commercially manufactured under the pharmaceutical name of Abraxane®, nab-paclitaxel is an effective chemotherapeutic used to treat advanced and spreading pancreatic cancers, metastatic breast cancers, and non-small lung cancers. The active molecule, solvent-based paclitaxel, is highly toxic and causes severe side effects for patients, which can be significantly reduced by applying HSA as a carrier for drug delivery.

Human serum albumin (HSA) is a valuable material for nanoparticle (NP) preparation due to its improved biocompatibility, biodegradability, non-toxicity, and non-immunogenicity properties. Nab-paclitaxel is formulated by encapsulating the paclitaxel molecule inside the naturally occurring human serum albumin (HSA).

 

THE SPEAKERS:

Dr. Liye Maeyama

As Biotest AG's Global Product Manager, Dr. Liye Maeyama is currently focused on the assessment of various characteristics of albumin (for example redox state of Cysteine 34, binding characteristics, purity) and its effect on albumin excipient application in nanoencapsulation, and in induced pluripotent stem cells. Dr. Liye Maeyama earned a Ph. D. in Biochemistry from Cologne University (Germany).

Matt Laferriere

As a Microfluidics’ Applications Engineer, Matt Laferriere has an in-depth understanding of a wide variety of applications, including nanoemulsions, cell disruption and nanoparticles. During his tenure, Matt has amassed extensive knowledge performing proof of concept, process optimization, and scale-up tests at the Westwood, MA facility. Matt earned a Bachelor of Science in Chemical Engineering and a Minor in Mathematics and Nuclear Engineering from the University of Rhode Island.

Dr. Carolin Tetyczka

Since August 2021, Dr. Carolin Tetyczka has been a Senior Scientist at the Research Center Pharmaceutical Engineering (RCPE) focusing on manufacturing and characterization of nano drug delivery systems. Dr. Tetyczka holds a Ph. D. with her thesis titled, “(Bio)pharmaceutical investigations of nano drug delivery systems.” Dr. Tetyczka holds a diploma in pharmacy from the University of Graz.